Table 2.
Evaluation of significant differences between different phases of chronic HBV patients by using Kruskal-Wallis ANOVA (A = EPI vs. EPH; B = EPI vs. ENI; C = EPI vs. ENH; D = EPH vs. ENI-HR; E = EPH vs. ENI; F = EPH vs. ENH; G = EPH vs. ENI-HR; H = ENI vs. ENH; I = ENI vs. ENI-HR; J = ENH vs. ENI-HR).
| Analyte | P value | Q Value | Group |
|---|---|---|---|
| HBV DNA | 5.42 × 10−120 | 4.35 × 10−119 | ABCDEFGHIJ |
| HBsAg | 1.47 × 10−37 | 5.89 × 10−36 | ABCDEFGHI |
| CXCL10 | 5.80 × 10−18 | 1.16 × 10−17 | ACEGHJ |
| Age | 1.13 × 10−17 | 1.81 × 10−17 | ABCDEFIJ |
| ALT | 4.23 × 10−11 | 3.15 × 10−11 | ACEGHJ |
| CCL4 | 1.18 × 10−8 | 6.31 × 10−9 | EGHJ |
| IL-17 | 3.92 × 10−8 | 1.97 × 10−8 | EGHJ |
| TGF-β2 | 3.93 × 10−7 | 1.86 × 10−7 | DGIJ |
| TNF-α | 7.85 × 10−4 | 2.86 × 10−4 | CHJ |
| IL-12p70 | 2.58 × 10−3 | 8.12 × 10−4 | EH |
| IL-16 | 2.83 × 10−3 | 8.74 × 10−4 | CFHJ |
| IFN-γ | 9.99 × 10−3 | 2.82 × 10−3 | CH |